Skip to Main Content

Rise and shine, everyone, another busy day is on the way. We can tell because we have already made the rounds at the local airport, where we scooped up one of the short people and are now busy arranging our calendar for the next few hours. No doubt, you can relate. So time to fire up the coffee kettle, yes? Our choice today is gingerbread spice. As always, you are welcome to join us. We enjoy the company. Now, though, it is time to get cracking. So here is the latest laundry list of interesting items for you to peruse. We hope you have a meaningful and productive day. And of course, do keep in touch. As the first item indicates, we accept secret dossiers. …

Bausch Health is being investigated by U.S. authorities in connection with marketing of four medicines used to treat different skin conditions, STAT reports. The U.S. Department of Justice sent a civil investigative demand last year to the company seeking information about various activities in which the medicines may have been promoted for uses not approved by regulators. The inquiry is focused on three drugs used to treat plaque psoriasis — Bryhali, Siliq, and Duobrii – and a fungal treatment called Jublia. The Justice Department is also interested in any financial assistance that may have been provided to Medicare patients who were prescribed Siliq.


McKinsey repeatedly allowed employees who served pharmaceutical companies, including opioid makers, to also consult for the U.S. Food and Drug Administration, The New York Times writes, citing documents released by the House Committee on Oversight and Reform and a coalition of state attorneys general. The records detail work McKinsey did for Purdue Pharma and other opioid manufacturers over a 15-year period, from 2004 to 2019. Since 2010, at least 22 McKinsey consultants have worked for both Purdue and the F.D.A., some at the same time. McKinsey also allowed employees advising Purdue to help shape materials that were intended for government officials and agencies.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.